Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 2, 2026

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Non-small-cell lung cancer.

Peter Goldstraw1, David Ball, James R Jett

  • 1Academic Department of Thoracic Surgery, Royal Brompton and Harefield NHS Foundation Trust, Imperial College School of Medicine, London, UK. p.goldstraw@rbht.nhs.uk

Lancet (London, England)
|May 14, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ki67 proliferation index augments two-tier tumour grade in prediction of survival and progression-free survival in epithelioid pleural mesothelioma.

ERJ open research·2026
Same author

The 2025 ATS/ERS update of the international multidisciplinary classification of the interstitial pneumonias: implications for the pathologist.

Histopathology·2026
Same author

Machine Learning Assessment of Pathologic Response in Lung Cancer Resections After Neoadjuvant Therapy-IASLC MPR Project.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Association of bronchoalveolar lavage cellular analysis and radiological findings in fibrotic interstitial lung diseases.

BMJ open respiratory research·2026
Same author

Bronchiolocentric interstitial pneumonia is a more accurate interstitial lung disease classification than hypersensitivity pneumonitis: pro.

American journal of respiratory and critical care medicine·2026
Same author

Rebuttal to "Bronchiolocentric interstitial pneumonia is a more accurate interstitial lung disease classification than hypersensitivity pneumonitis: con".

American journal of respiratory and critical care medicine·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
See all related articles

Recent advancements in non-small-cell lung cancer (NSCLC) include updated classifications, earlier diagnosis via CT screening, and improved treatments like new chemotherapy and surgical approaches. These enhance patient outcomes for lung cancer.

Area of Science:

  • Oncology
  • Pulmonology
  • Medical Diagnostics

Background:

  • Significant progress in non-small-cell lung cancer (NSCLC) management has occurred since the last major review.
  • The field has seen evolution in classification, diagnostic techniques, and therapeutic strategies.

Purpose of the Study:

  • To review and synthesize key advancements in NSCLC over the past decade.
  • To provide an expert consensus on updated epidemiological and pathological classifications.
  • To highlight progress in early diagnosis, staging, and treatment modalities.

Main Methods:

  • Convened an international panel of experts to analyze recent developments.
  • Reviewed changes in NSCLC epidemiology and pathological classification.
  • Assessed the impact of CT screening and other diagnostic tools.

Related Experiment Videos

Last Updated: Jun 2, 2026

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

  • Examined the seventh edition of the TNM classification and its prognostic implications.
  • Evaluated new chemotherapy agents, adjuvant chemotherapy, radiotherapy techniques, and surgical approaches.

    • Main Results:

    • The seventh edition of the TNM classification offers improved prognostic stratification.
    • CT screening shows potential for earlier non-small-cell lung cancer detection.
    • New chemotherapy agents and adjuvant chemotherapy demonstrate efficacy in specific patient groups.
    • Advances in radiotherapy planning and administration, alongside refined surgical techniques, are improving treatment outcomes.

    Conclusions:

    • The past decade has brought substantial improvements in the classification, diagnosis, and treatment of non-small-cell lung cancer.
    • Integrated approaches combining updated staging, early detection, and novel therapies are crucial for better patient management.
    • Continued research and expert collaboration are essential to further advance lung cancer care.